ABSTRACT: Phosphodiesterase (PDE) 7 is involved in pro-inflammatory processes being widely expressed both on lymphocytes and on certain brain regions. Specific inhibitors of PDE7 have been recently reported as potential new drugs for the treatment of neurological disorders due to their ability to increase intracellular levels of cAMP and thus, modulating the inflammatory process, as a neuroprotective well-established strategy. Multiple sclerosis is an unmet disease in which pathologies on inmunitary system, T-cells, and specific neural cells are involved simultaneously. Therefore, PDE7 inhibitors able to interfere with all these targets may represent an innovative therapy for this pathology.
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INTRODUCTION
The nucleotides cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP) are two ubiquitous second messengers that mediate a variety of cellular responses. Two enzymatic processes control the intracellular levels of these nucleotides: the first one by regulation of their synthesis, achieved through the action of adenylate or guanylate cyclase, and the second one through their hydrolysis catalyzed by phosphodiesterases (PDEs). 1 Up to now there are 11 known families of PDEs that control the levels of cAMP and cGMP by catalyzing their hydrolysis to AMP or GMP, respectively. The family members are classified according to their sequence identity, cellular distribution, substrate specificity, and sensitivity to different PDE inhibitors, 2, 3 being good targets for pharmacological intervention. In fact, one of the greatest advances in the PDE field in the last 15 years has been the increased availability and more recently the clinical use of family-selective inhibitors. 4 Therefore, PDE inhibitors may have considerable therapeutic utility as anti-inflammatory agents, antiasthmatics, vasodilators, smooth muscle relaxants, cardiotonic agents, antidepressants, antithrombotics, and agents for improving memory and other cognitive functions. 5 The members of the PDE superfamily are well placed to be targets for pharmacological intervention. As elevation of intracellular cAMP level shows immunosuppressive and anti-inflammatory properties, 1, 6 selective inhibitors of cAMPspecific PDEs have been widely studied as therapeutic agents for the treatment of human diseases. 5 The PDEs responsible for controlling specifically the intracellular levels of this nucleotide are PDE4, PDE7 and PDE8. More information is known about PDE4 being involved in the hydrolysis of cAMP within immune and central nervous system (CNS) cells. Thus, PDE4 inhibitors have been widely studied as efficient antiinflammatory agents for different diseases. 7 However, a major drawback of these 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 compounds is the significant emetic effects. To overcome these adverse effects, several strategies have been developed. 8 An alternative approach is to target different cAMP specific PDEs families as PDE7 9 expressed also in T-cells and CNS and being a good target for the control of neuroinflammation. 10 The PDE7 family is composed of two genes, PDE7A and PDE7B. High mRNA concentrations of both PDE7A and PDE7B are expressed in rat brain and in numerous peripheral tissues, although the distribution of these enzymes at the protein levels has not been reported. Within the brain PDE7A mRNA is abundant in the olfactory bulb, hippocampus, and several brain-stem nuclei. 11 The highest concentrations of PDE7B transcripts in the brain are found in the cerebellum, dentate gyrus of the hippocampus and striatum. 12, 13 There is very little information regarding the physiological functions regulated by PDE7. It has been shown that PDE7 is involved in pro-inflammatory processes and is necessary for the induction of T-cell proliferation. 14 Several years ago, our research group was the first one in reporting the first PDE7 selective inhibitors. 16 Since then, a lot of efforts have been done to increase potency and selectivity of this kind of compounds, conforming a great variety of diverse chemical compounds with interesting pharmacological profiles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Following our on-going research on this field, we have recently demonstrated that PDE7 inhibitors belonging to the quinazoline family enhance neuroprotection and decrease neuroinflammation in well-characterized cellular and animal models of Parkinson's disease, 18 spinal cord injury, 19 and stroke. 20 With the aim to design potent and specific PDE7 inhibitors, we developed a pharmacophore model for PDE7A1 inhibitors using Catalyst/Hypogen program to identify the chemical features that are responsible for the inhibitory activity. 21 Four pharmacophore features, such as one hydrogen bond acceptor, one aromatic ring and two hydrophobic aliphatic points were identified to be involved in inhibitor-PDE7 According to this procedure, three new hits (1-3) were found as potential PDE7A1
inhibitors structurally diverse from those previously known 22 (Table 1) . Then, the biological activity of the hits was calculated using the catalytic domain of PDE7A1 and a radiometric assay.
Here, Chart 1
Here, Table 1 Page 6 of 48 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 These three hits were selected for further medicinal chemistry programs aimed to increase not only efficacy but also the ADME profile to be considered for further drug development in the neurodegenerative field. Here, the results obtained in the development of the family derived from the furan 1 and its therapeutic potential for multiple sclerosis are reported.
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
RESULTS AND DISCUSSION
Chemistry. The 5-(2-methyl-4-nitrophenyl)-2-furylmethyl 3,4,5-triethoxybenzoate
(1) has a furan heterocycle between two substituted phenyl rings moieties. In particular, the structural modifications proposed are based on the modification of the number and nature of substituents attached to both phenyl rings and the variation of the linker between the furan and the alkyloxyphenyl ring (Chart 2).
Here, Chart 2
The synthetic routes for the preparation of the furan derivatives are summarized in Schemes 1 and 2. The 5-phenyl-2-furylmethyl benzoate derivatives (Scheme 1) were obtained in one synthetic step, after the coupling reaction of the alkyloxybenzoic acid and the corresponding 5-phenyl-2-furylmethanol. These furan alcohols were commercial available with the only exception of 5-(2,4-dichlorophenyl)-2-furylmethanol (4) which was synthesized by reduction of the 5-(2,4-dichlorophenyl)-2-furoic acid with lithium aluminum hydride as described in the supporting information.
Here, Scheme 1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 The synthesis of benzyl 5-phenylfuroate and benzyl 5-phenylfuramide derivatives (Scheme 2) involved the coupling of alkyloxybenzyl alcohol or alkyloxybenzyl amine with the furoic acid derivative. Among different coupling reagents previously used, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was chosen as the most convenient one.
The structures of all the synthesized products were unequivocally confirmed by mass spectrometry, elemental analysis, and 1 H and 13 C NMR spectroscopic data.
Here, Scheme 2
In vitro evaluation of PDE7 inhibition. The new derivatives here synthetized were tested for their inhibitory potencies against PDE7A1 using recombinant human isoenzyme as described in the experimental section. All the compounds were tested at a fixed concentration (10 µM) by duplicate. The percentage of inhibition obtained on PDE7A1 for all the compounds at this concentration is showed in Table 2 . From these data we can conclude that several new compounds are inhibitors of PDE7A1.
Here, Table 2 As the biological assay conditions differs from that previously used, 22 the lead compound 1 was also here evaluated to compare the data with the new synthesized derivatives. Noteworthy is the fact that when the lead compound 1 was evaluated in the new experimental conditions using the complete enzyme instead of the catalytic domain of PDE7A1, only a 29% of PDE7A1 inhibition at 10 µM was found. Regarding this Here, Table 3 Here, Figure 1 Docking studies. In order to gain some insight in the binding mode of our family of compounds, docking experiments were carried out with help of Surflex method implemented in Sybyl according to the procedure described in the experimental section.
Considering the kinetic studies results, the docking studies were focused on the cAMP binding site. After careful examination of docking solutions two binding modes that can draw the chemical structure biological activity relationships (SAR) in this serie of compounds were proposed. In fact, the different substituents and their location (ortho, meta or para) when R 3 is a phenyl ring, determine which binding mode is selected. The mainly binding mode (namely "A" from now) is characterized by a hydrophobic interaction of the phenyl group in R 3 with Val380 and a NH-π interaction 23, 24 with Gln413, which is in fact, a conserved residue among PDEs families. 25 A clearly example of this binding mode is compound 13 (see figure 2) . In addition to these interactions, the furan moiety contributes to increase inhibition by means of a stacking interaction with another conserved residue as Phe416. Furthermore, the 3,4,5-trimethoxy-phenyl ligand's moiety is located in a pocket where the ligand can take benefit of a hydrogen bond between the methoxy group in R 2 and the proton H ε of His256 group (d Hε…O = 2.7Å) and a hydrophobic interaction with Phe384.
Here, Figure 2 When R 1 and R 2 are ethoxy groups (compound 24), the binding mode remains mode "A", (see figure 3 ). The presence of these bigger substituents forces the ligand to reorient the ester group keeping a hydrophobic interaction with Phe384. This new location causes a weakening of the parallel stacking interaction between the furan ring and Phe416 (found for compound 13) because of the displacement of the furan ring in order to keep the hydrophobic interaction between ligand's benzene ring in R 3 and
Val380. As a result, compound 24 shows a lower percentage of PDE7A1 inhibition than compound 13 (table 2) .
Here, Figure 3 Regarding the substituent located in para position in the phenyl attached in R 3 such a methyl group (compound 23), the ligand orients this substituent facing it towards the Here, Figure 5 In vitro antiinflamatory studies. Our next step was to explore whether these new PDE7 inhibitors are able to reduce the inflammatory response in different cell based assays. Thus, we used primary cultures of astrocytes and microglia treated with lipopolysaccharide (LPS), a potent inflammatory agent.
The potential anti-inflammatory activity of the selected PDE7 inhibitors (7, 13, 14, 19 and 31) was measured by evaluating the production of nitrites from primary cultured glial cells (astrocytes and microglia). To asses the safety of the compounds on cell 7 ) a significant induction of nitrite production in the culture medium, was produced, while if the PDE7 inhibitors were in the medium a significant decrease of nitrite production was observed as a consequence of a reduction of the inflamatory cell response by the drug treatment.
We used as standard references the well known PDE4 inhibitor Rolipram and the PDE7 inhibitor BRL50481. 26 These compounds showed a neuroprotective effect which was in accordance with our previously reported results, 20 confirming that these cell permeable PDE7 inhibitors are able to decrease neural inflammatory activation.
Here, Figure 6 Here, Figure 7 Candidate selection for in vivo studies. The final aim of our study was to proof the potential efficacy of these new PDE7 inhibitors in a multiple sclerosis murine model.
The selection of the candidate for in vivo studies was done based on pharmacological and pharmacokinetic properties. Recently, potential cardiotoxic effect of long-term PDE3A inhibition was reported. 27 Thus, to avoid adverse effects in further development steps we measured the inhibition on PDE3A of our selected compounds (Table 4) .
Here, Table 4 Considering these new data, almost every derivative tested inhibit PDE3A at the same concentration that PDE7A1 was also inhibited, showing a lack of selectivity and opening safety concerns in further pharmacological development. However, derivative
13 shows an IC 50 value tenfold higher on PDE3A regarding PDE7A1 (ratio PDE7A1/PDE3A=0.09), selecting this candidate for the next studies.
To evaluate isoenzyme specificity of 13, inhibition of different cAMP isoenzymes was determined (Table 5 ). While marginal inhibition was found on PDE4B2, no activity was found on PDE7B and PDE4D3. The partial inhibition of PDE4B2 may increase the biological action of 13 in vivo because cAMP levels might be enhanced. Moreover, it is worth mentioning that inhibition of PDE4D3 is associated to the adverse emetic effects in the development of PDE4 inhibitors. 28 As derivative 13 does not inhibit this specific isoenzyme, its safety potential regarding PDEs inhibition is reinforced.
Here, Table 5 We also check the ability of derivative 13 to regulate intracellular cAMP levels in cell cultures. Two different compound concentrations (10 and 30 µM) were used and in both cases we observed an increase of cAMP even more effective than the reported PDE7 inhibitor BRL50481 26 ( Figure 8 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Here, Figure 8 Finally, and to decipher if this compound has the drug profile to be administered in vivo, we determined its ability to cross the blood-brain barrier (BBB), one of the major obstacles for the treatment of diseases in the central nervous system. The majority of compounds enter the brain by transcellular passive diffusion, which is driven by a concentration gradient between the blood and the brain. 29 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 treatment of multiple sclerosis is here disclosed. We presented the medicinal chemistry program around one hit found by using a pharmacophore model. The work lead to a novel serie of PDE7 inhibitors, chemically diverse from those known and containing a furan ring in their chemical structure.
The biological profile has been well characterized showing an increase of cAMP level and a reduction of the inflammatory response in primary neural cell cultures.
Moreover, a clear strategy to select the best compound for in vivo testing, using pharmacodynamic and pharmacokinetic criteria was followed. Finally, compound 13
was chosen due to its PDE7 selectivity and its ability to cross the BBB. This compound is able to reverse clinical symptoms in an EAE mice model. All together these data supported the potential of PDE7 inhibitors for the therapeutic pharmacological treatment of multiple sclerosis. Typical spectral parameters: spectral width 10 ppm, pulse width 9 μs (57°), data size 32 K. 13 C NMR experiments were carried out on the Bruker AVANCE-300 spectrometer operating at 75 MHz or on a Varian INOVA 400 spectrometer working at 100 MHz. IC 50 values were calculated by non-linear regression fitting using GraphPad Prism.
3,4,5-Trimethoxybenzyl 5-(4-methyl-2-nitrophenyl)-2-furamide (31
Data (radioactivity vs log concentration) was fitted to a sigmoidal dose-response equation: Y = Bottom + (Top-Bottom)/(1+10^((logIC 50 -X)*n)), where Bottom and Top were the minimum and maximal inhibition for PDE, respectively, IC 50 was the concentration of compound that inhibited the PDE activity in a 50% and n was the slope of the concentration-response curve. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 terminal residues with neutral ends. Then, newly added hydrogen positions were optimized with MMFF94 force field until a 0.01kcal/mol gradient was reached. Ligand geometries were also minimized with MMFF94 force field until a 0.01kcal/mol gradient was reached.
The docking studies were performed with Surflex (Sybyl). An "Automatic" protocol was generated and dockings were carried out using 20 initial conformations for each ligand allowing flexibility. Pre and post minimization was used considering 100 solutions in each case. Cscore scoring function was used with all the four options and claiming for a relaxed structure.
Visual inspection of solutions of selected ligands was carried out in order to find which ones allow the best agreement with SAR data. Finally the selected ligandcomplex geometries were minimized with MMFF94 force field until a 0.01kcal/mol gradient was reached.
To test our docking protocol and validate the procedure, we carried out docking experiments for some selected 3D structures The first one was for the complex of 3,5-dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester bound to PDE4D
(pdb code 1Y2K), as this ligand shares a high similarity with some of our inhibitors.
The high similarity between the docked solution (only one cluster within 2.0Å rmsd of heavy atoms was found) and the experimental one gave us confidence in our protocol (rmsd 0.2Å of heavy atoms vs exp., see figure S2 in the supporting information). In fact, the main difference between both orientations is related with the benzene with supports a nitro group. This difference can be explained due to the lack of water W1016 from the pdb, which was not present in the model of PDE4D used for docking were only the metal coordination waters (W1003-W1008) were retained. On the other hand, in order to test our protocol specifically in PDE7, we carried out the docking experiment with figure S3 in the supporting information) when waters W573
and W542 were added aside with the metal coordination waters (W504-W509). This fact is not surprising as those two additional water molecules are within 3.0Å from the ligand. As only those two structures of PDE7A were available at the moment of this study (pdb codes. 1ZKL, 3G3N), and given the redocking results obtained for 3G3N we decided to use structure 1ZKL for docking purposes. Finally, as the best redocking results were obtained for structure 1Y2K, which ligand is the most similar to our inhibitors, we decided to retain only the metal coordination waters present in pdb code 1ZKL for docking.
Primary cell cultures.
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Compound
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